Vera Therapeutics said final two-year Phase 3 data for Trutakna (deterioration pathway therapy for IgA nephropathy) strengthened its case for full FDA approval. The company reported that the drug stabilized kidney function and reduced the risk of kidney-related death and other complications, supporting a fourth-quarter submission plan. Trutakna received accelerated approval in July for IgA nephropathy. The final, longer-term dataset now provides the durability and outcomes evidence typically needed for conversion to traditional approval. For sponsors and nephrology stakeholders, the development is significant because it can affect prescribing patterns and payer behavior in IgAN, where long-term renal endpoints drive guideline adoption. The near-term focus shifts to FDA review timelines and whether the Phase 3 primary/secondary endpoint framing aligns with how the agency will consider conversion risk reduction claims.